https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-25 / Res Vet Sci 2021 Jul;139:159-165
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-25 / Res Vet Sci 2021 Jul;139:159-1652021-07-25 00:00:002021-07-25 00:00:00Evaluation of the oncolytic property of recombinant Newcastle disease virus strain R2B in 4T1 and B16-F10 cells in-vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-18 / Saudi J Biol Sci 2021 Oct;28(10):5833-5840
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-18 / Saudi J Biol Sci 2021 Oct;28(10):5833-58402021-06-18 00:00:002023-01-31 13:08:35Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-17 / Mol Cancer Ther 2021 Sep;20(9):1723-1734
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-17 / Mol Cancer Ther 2021 Sep;20(9):1723-17342021-06-17 00:00:002023-01-31 13:09:00Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-27 / BMC Cancer 2021 May;21(1):625
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-27 / BMC Cancer 2021 May;21(1):6252021-05-27 00:00:002021-05-27 00:00:00Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-12 / Virol J 2021 May;18(1):98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-12 / Virol J 2021 May;18(1):982021-05-12 00:00:002021-05-12 00:00:00A bibliometric review of oncolytic virus research as a novel approach for cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-04-21 / Oncol Lett 2021 Jun;21(6):482
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-04-21 / Oncol Lett 2021 Jun;21(6):4822021-04-21 00:00:002023-01-31 13:10:15MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-03-30 / Int J Med Sci 2021;18(11):2294-2302
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-03-30 / Int J Med Sci 2021;18(11):2294-23022021-03-30 00:00:002023-01-31 13:10:47Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-02-01 / Neurosurg Focus 2021 02;50(2):E8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-02-01 / Neurosurg Focus 2021 02;50(2):E82021-02-01 00:00:002021-02-01 00:00:00The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-12-24 / Cancers (Basel) 2020 Dec;13(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-12-24 / Cancers (Basel) 2020 Dec;13(1)2020-12-24 00:00:002021-11-15 13:17:14Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-12-08 / PeerJ 2020;8:e9761
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-12-08 / PeerJ 2020;8:e97612020-12-08 00:00:002020-12-08 00:00:00Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice
